ProPhase Labs Future Growth

Future criteria checks 5/6

ProPhase Labs is forecast to grow earnings and revenue by 77.4% and 86.3% per annum respectively while EPS is expected to grow by 44.4% per annum.

Key information

77.4%

Earnings growth rate

44.4%

EPS growth rate

Pharmaceuticals earnings growth	23.7%
Revenue growth rate	86.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	27 Aug 2024

Recent future growth updates

Recent updates

Investors Give ProPhase Labs, Inc. (NASDAQ:PRPH) Shares A 65% Hiding

Nov 09

It's Down 65% But ProPhase Labs, Inc. (NASDAQ:PRPH) Could Be Riskier Than It Looks

Nov 09

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Jul 03

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Mar 04

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Jan 09

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Sep 21

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Apr 07

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Jul 21

ProPhase Labs: A Stellar Quarter And Another Special Dividend

May 16

Earnings and Revenue Growth Forecasts

NasdaqCM:PRPH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	95	6	N/A	N/A	1
12/31/2025	50	-16	N/A	N/A	1
12/31/2024	15	-24	N/A	N/A	1
9/30/2024	13	-28	-17	-14	N/A
6/30/2024	18	-26	-18	-15	N/A
3/31/2024	29	-24	-21	-17	N/A
12/31/2023	44	-17	-15	-11	N/A
9/30/2023	63	-10	-14	-10	N/A
6/30/2023	79	-4	-6	-3	N/A
3/31/2023	94	7	5	9	N/A
12/31/2022	123	18	25	29	N/A
9/30/2022	146	31	21	23	N/A
6/30/2022	131	27	13	15	N/A
3/31/2022	111	18	13	15	N/A
12/31/2021	79	6	-18	-14	N/A
9/30/2021	39	-5	-21	-16	N/A
6/30/2021	33	-2	-16	-11	N/A
3/31/2021	28	0	-16	-11	N/A
12/31/2020	15	-2	-4	-3	N/A
9/30/2020	12	-2	3	4	N/A
6/30/2020	11	-2	3	3	N/A
3/31/2020	9	-3	-2	-2	N/A
12/31/2019	10	-3	-1	-1	N/A
9/30/2019	11	-3	-1	-1	N/A
6/30/2019	11	-4	-2	-2	N/A
3/31/2019	12	-3	-1	-1	N/A
12/31/2018	13	-2	-2	-2	N/A
9/30/2018	13	-1	-3	-3	N/A
6/30/2018	14	-1	N/A	-2	N/A
3/31/2018	13	-1	N/A	-6	N/A
12/31/2017	10	-2	N/A	-3	N/A
9/30/2017	6	-3	N/A	-1	N/A
6/30/2017	5	-3	N/A	-1	N/A
3/31/2017	4	-3	N/A	2	N/A
12/31/2016	4	-4	N/A	0	N/A
9/30/2016	-6	-3	N/A	-2	N/A
6/30/2016	-3	-2	N/A	-4	N/A
3/31/2016	-2	-2	N/A	-5	N/A
12/31/2015	3	-2	N/A	-3	N/A
9/30/2015	21	-3	N/A	-4	N/A
6/30/2015	22	-7	N/A	-3	N/A
3/31/2015	22	-8	N/A	-4	N/A
12/31/2014	22	-8	N/A	-3	N/A
9/30/2014	23	-7	N/A	-1	N/A
6/30/2014	24	-2	N/A	-1	N/A
3/31/2014	24	-1	N/A	0	N/A
12/31/2013	25	0	N/A	1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: PRPH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PRPH is expected to become profitable in the next 3 years.

Revenue vs Market: PRPH's revenue (86.3% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: PRPH's revenue (86.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PRPH's Return on Equity is forecast to be high in 3 years time

ProPhase Labs Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

ProPhase Labs, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Price target decreased by 7.5% to US$18.50

Price target decreased by 7.5% to US$18.50

Consensus revenue estimates fall by 16%

Consensus EPS estimates fall by 46%

Consensus estimates of losses per share improve by 19%

Recent updates

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

ProPhase Labs, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Investors Give ProPhase Labs, Inc. (NASDAQ:PRPH) Shares A 65% Hiding

It's Down 65% But ProPhase Labs, Inc. (NASDAQ:PRPH) Could Be Riskier Than It Looks

ProPhase Labs, Inc. has completed a Follow-on Equity Offering in the amount of $3.0024 million.

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc. has completed a Follow-on Equity Offering in the amount of $3.0024 million.

ProPhase Labs Receives Non-Compliance Notice from Nasdaq Regarding Listing Rule 5605(c)(2)(A)

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc., Annual General Meeting, Jun 20, 2024

ProPhase Labs, Inc. to Report Q1, 2024 Results on May 09, 2024

ProPhase Labs, Inc. Unveils Project ZenQ-AI

ProPhase Labs, Inc. announced delayed annual 10-K filing

ProPhase Labs, Inc. to Report Fiscal Year 2023 Results on Mar 15, 2024

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Prophase Labs, Inc. Announces Important Developments in the Company’s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test

ProPhase Labs, Inc. Announces Preliminary Positive Results for Dietary Supplement Equivir

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Consensus revenue estimates fall by 16%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ProPhase Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Consensus EPS estimates fall by 46%

New minor risk - Market cap size

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

First quarter 2023 earnings released: EPS: US$0.033 (vs US$0.81 in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

ProPhase Labs, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Investor sentiment deteriorates as stock falls 17%

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

Consensus estimates of losses per share improve by 19%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs, Inc. to Report Q1, 2023 Results on May 11, 2023

Investor sentiment improves as stock rises 18%

Price target increased by 13% to US$17.00

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

ProPhase Labs, Inc. Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Chairman & CEO exercised options and sold US$2.0m worth of stock

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Chairman & CEO exercised options and sold US$2.8m worth of stock

ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million.

ProPhase Labs, Inc. Announces Executive Changes

ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million.

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% undervalued after recent price drop

ProPhase Labs, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Chairman & CEO exercised options and sold US$3.1m worth of stock

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

ProPhase Labs, Inc. Announces Resignation of Bill White as Chief Financial Officer

Consensus EPS estimates increase by 49%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs Q2 2022 Earnings Preview

ProPhase Labs, Inc. to Report Q2, 2022 Results on Aug 11, 2022

ProPhase Labs, Inc. (NasdaqCM:PRPH) announces an Equity Buyback for $6 million worth of its shares.

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

Investor sentiment deteriorated over the past week

ProPhase Labs to license two investigational cancer compounds from Global BioLife